Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Dermatology

Journal Scan / Research · January 15, 2024

Aggregate Response Benefit in Skin Clearance and Itch Reduction With Upadacitinib vs Dupilumab in Patients With Moderate to Severe Atopic Dermatitis

Dermatitis

 

Additional Info

Disclosure statements are available on the authors' profiles:

Dermatitis
Aggregate Response Benefit in Skin Clearance and Itch Reduction With Upadacitinib or Dupilumab in Patients With Moderate-to-Severe Atopic Dermatitis
Dermatitis 2023 Dec 18;[EPub Ahead of Print], JI Silverberg, M de Bruin-Weller, BM Calimlim, X Hu, SA Ofori, AM Platt, HD Teixeira, K Eyerich, JP Thyssen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading